MatriSys Bioscience Inc. is pleased to announce that we have been selected as a CONNECT 2020 Cool Company
May 28, 2020 14:11 ET
|
MatriSys Bioscience
SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by...
MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors
May 26, 2020 12:25 ET
|
MatriSys Bioscience
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed...
MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors
May 19, 2020 03:09 ET
|
MatriSys Bioscience
SAN DIEGO, May 19, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis
March 20, 2019 19:55 ET
|
MatriSys Bioscience
SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...
MatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of Directors
March 11, 2019 03:11 ET
|
MatriSys Bioscience
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin...
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
January 03, 2019 03:01 ET
|
MatriSys Bioscience
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has...
MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors
November 12, 2018 04:11 ET
|
MatriSys Bioscience
SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis
August 21, 2017 06:00 ET
|
MatriSys Bioscience
SAN DIEGO, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced that the first patient...
MatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitis
February 22, 2017 17:39 ET
|
MatriSys Bioscience
SAN DIEGO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience (MatriSys Bio) is pleased to announce the publication of breakthrough scientific results from the laboratory of Dr. Richard Gallo at...